Zura Bio (ZURA) Projected to Post Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Zura Bio to announce earnings of ($0.22) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Tuesday, October 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). On average, analysts expect Zura Bio to post ($0.82) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

Zura Bio Stock Up 0.8%

ZURA opened at $4.02 on Thursday. The firm has a market capitalization of $385.24 million, a P/E ratio of -3.59 and a beta of 0.03. The stock has a fifty day moving average of $4.53 and a 200-day moving average of $5.22. Zura Bio has a 12-month low of $3.25 and a 12-month high of $7.44.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ZURA shares. William Blair initiated coverage on Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Wedbush raised their price objective on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Guggenheim reiterated a “buy” rating on shares of Zura Bio in a report on Friday, October 30th. Finally, Weiss Ratings raised shares of Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.00.

Zura Bio Company Profile

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.